Financial Consulate’s Summit Therapeutics SMMT Stock Holding History

Financial Consulate’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.46K	Buy	+500	New	+$7.48K	﹤0.01%	737

Other funds holding SMMT

Griffin Asset Management New York $934M AUM 18.69% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Wealth Management Partners Tucson, Arizona $426M AUM 43.17% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return

Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return

Financial Consulate's SMMT Position: Q3 2026 in Review

Financial Consulate opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 500 shares worth $8.46K. The stake represents ﹤0.01% of the portfolio and ranks #737 among its holdings.

37 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

Financial Consulate held 500 shares of Summit Therapeutics worth $8.46K as of Q3 2026.
Summit Therapeutics was a new Financial Consulate position in Q3 2026.
Summit Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #737 holding.
37 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.